April 2026 — Nine Diagnostics Engages with SCbio and MassBio on DRIVE Accelerator (Spring 2026)

Nine Diagnostics is participating in the Spring 2026 DRIVE Accelerator Biomarkers and Diagnostics track, run by SCbio in partnership with MassBio.

This program brings together emerging companies developing next-generation diagnostic and biomarker technologies, alongside industry mentors and ecosystem partners focused on accelerating clinical translation. DRIVE is backed by a network of leading strategic partners — including Eli Lilly, LabCorp, and others across pharma, diagnostics, and health systems — providing participating companies with direct access to industry decision-makers and potential commercialization partners.

Participation in DRIVE supports continued development of our nanosensor-enabled platform within the broader diagnostics and precision medicine landscape, with a focus on advancing strategic partnerships and real-world deployment pathways.

March 2026 — Biotools Innovator Pitch Event

Nine Diagnostics participated in the BioTools Innovator pitch event, a competitive platform spotlighting emerging companies building enabling technologies for life sciences and diagnostics. BioTools Innovator is recognized for elevating high-impact tool and platform companies that can accelerate research workflows and downstream clinical translation. During the event, we presented our nanosensor-enabled, machine learning-driven approach to capturing complex molecular fingerprints from small-volume samples, and how this foundation can support biomarker-agnostic diagnostics across challenging disease areas. Participation helped increase visibility with a targeted audience of investors, strategic partners, and ecosystem leaders focused on next-generation research and diagnostic platforms, and it supported new conversations around partnerships and commercialization pathways.

February 2026 — Nine Diagnostics Selected to Present at the FNIH Biomarkers Consortium 20th Anniversary Symposium

Nine Diagnostics was selected to present at the Foundation for the NIH (FNIH) Biomarkers Consortium 20th Anniversary Symposium in Rockville, Maryland — a leading forum convening senior leaders across academia, industry, and government to advance biomarker science.

This selection reflects growing recognition of our platform within the broader biomarker ecosystem and our alignment with consortium-driven efforts to accelerate clinical validation and adoption.

The symposium emphasized the importance of moving beyond traditional single biomarkers toward integrated, data-driven approaches. As highlighted by keynote speaker Dr. Eliav Barr (Chief Medical Officer, Merck), the field is increasingly focused on scalable, clinically actionable biomarker strategies that can improve decision-making across drug development and patient care.

Nine Diagnostics’ nanosensor-driven, machine learning-enabled platform directly aligns with this shift — enabling the detection of complex molecular signatures that can support patient stratification, treatment selection, and response monitoring in oncology.

January 2026 — Nine Diagnostics and Orbits Oncology Sign Letter of Intent (LOI)

Nine Diagnostics and Orbits Oncology have executed a Letter of Intent (LOI) to jointly develop a next-generation precision oncology diagnostics platform. This collaboration brings together two complementary, cutting-edge systems: Nine’s nanosensor-based molecular fingerprinting platform—which captures integrated disease signals directly from blood—and Orbit Oncology’s organoid-based functional drug-response platform, which measures how a patient’s tumor responds to therapies ex vivo. Together, they enable a closed-loop view of disease state and therapeutic efficacy. The partnership will focus initially on feasibility, including integrated workflow development, early multimodal dataset generation, and validation planning in oncology indications such as lung cancer and renal cell carcinoma. The objective is to generate the first combined datasets linking systemic molecular fingerprints with functional tumor response—creating a new category of precision diagnostics. This work builds directly on the platform Nine Diagnostics is commercializing and extends its capabilities into functional validation. It also reflects the broader ecosystem emerging around these technologies, including connections through the Merck Digital Sciences Studio, reinforcing the growing convergence of advanced sensing, AI-driven analytics, and functional oncology systems. The goal is to establish clear scientific and translational proof points that support downstream clinical development and commercialization pathways in precision oncology.

January 2026 — Nine Diagnostics Co-Founders Contribute to ARPA-H LIGHT Program

Nine Diagnostics co-founders Daniel Heller and Mijin Kim are part of the Weill Cornell Medicine team led by Lish Ndhlovu contributing to the ARPA-H LIGHT program.

This program focuses on advancing the ability to measure and interpret signals from the lymphatic system — a historically under-characterized but critical component of human biology — using AI-enabled nanosensor technologies.

While the lymphatic system has been difficult to study directly, its role in immune regulation, metastasis, and disease progression makes it highly relevant to oncology. Improved measurement of lymphatic dynamics has the potential to unlock new insights into cancer progression, treatment response, and recurrence monitoring.

This work also contributes to broader technology validation and de-risking of nanosensor-based diagnostic approaches, demonstrating the ability to extract clinically meaningful signals from complex biological systems.

December 2025 — New Publication: Machine Perception Liquid Biopsy for Brain Tumor Detection

We’re excited to highlight a recent publication from the lab of Nine Diagnostics co-founder Daniel Heller: “Machine perception liquid biopsy identifies brain tumours via systemic immune and tumour microenvironment signature,” published in Nature Nanotechnology (December 2025).

This work introduces a new paradigm for liquid biopsy, using nanosensor-derived signals combined with machine learning to detect brain tumors from blood. Rather than relying on predefined biomarkers, the method captures complex, system-level molecular patterns reflecting both tumor biology and the host immune response.

This approach is directly aligned with the core platform we are building at Nine Diagnostics. It reinforces the potential for biomarker-agnostic diagnostics in oncology, particularly for early detection and treatment monitoring in cancers where traditional biomarkers remain limited.

October 2025 — Nine Diagnostics Graduates from American Cancer Society BrightEdge Entrepreneurs Program

Nine Diagnostics graduated from the BrightEdge accelerator program, culminating in a Demo Day presentation highlighting our progress building a nanosensor-enabled, machine learning-driven diagnostic platform for oncology. BrightEdge, the impact investment and innovation arm of the American Cancer Society, supports companies advancing innovations across prevention, detection, and treatment to improve cancer outcomes. Through the program, we benefited from structured mentorship and feedback on scientific strategy, clinical translation, and early go-to-market planning. The accelerator also helped strengthen our positioning within the oncology innovation ecosystem by connecting us with a network of operators, partners, and mission-aligned stakeholders focused on moving high-impact technologies from the lab toward real-world clinical adoption. Graduation from BrightEdge marks an important milestone in our company’s growth, reinforcing both the relevance of our approach and our momentum toward validation and deployment.

September 2025 — Nine Diagnostics Selected for Biotech Investor Day

Nine Diagnostics was selected to present at Biotech Investor Day, a curated forum hosted by LabCentral connecting high-potential biotech and diagnostics companies with leading investors and strategic partners — including Johnson & Johnson, Pfizer, Eli Lilly, Merck, Novartis, and other top-tier life sciences organizations. Being chosen to present in this setting reflects growing interest in our approach and provided a direct opportunity to share our vision for a biomarker-agnostic, nanosensor-driven platform that uses machine learning to translate complex molecular patterns into clinically actionable insights. During the event, we highlighted our progress in building a scalable diagnostic foundation for oncology applications, including early detection and treatment response monitoring, and discussed our roadmap toward clinical validation and commercialization. Participation enabled targeted conversations with investors and senior partners from across the life sciences ecosystem — organizations that are actively shaping the future of diagnostics, precision medicine, and AI-enabled healthcare — helping expand our network for future fundraising and strategic collaboration.